Showing 708 results
-
Media Release /
-
Media Release /- One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA- Annualized cost of Zolgensma is USD 425,000…
-
Media Release /- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]-…
-
Media Release /
-
Media Release /
-
Media Release /- Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO- Primary results…
-
Media Release /-The Solutions to Empower Patients (STEP) Program™ continues to help nonprofit organizations deliver new solutions to address unmet patient needs-This year's focus is on addressing some of the most…
-
Media Release /
-
Media Release /
-
Media Release /- Voluntary recall of three lots issued after discovering potential cross contamination at a third-party manufacturer- Patients taking Promacta 12.5 mg for oral suspension should contact 1-866-918-…
